How Analysts Feel About Curis Inc (NASDAQ:CRIS) After Increase in Sellers?

Curis, Inc. (NASDAQ:CRIS) Logo

Investors sentiment decreased to 0.01 in Q2 2018. Its down 0.85, from 0.86 in 2018Q1. It dropped, as 66 investors sold Curis, Inc. shares while 1 reduced holdings. 1 funds opened positions while 0 raised stakes. 4.06 million shares or 93.46% less from 62.11 million shares in 2018Q1 were reported.
Renaissance Technology Limited holds 3.95 million shares or 0% of its portfolio. 98,344 were accumulated by Bain Pub Equity Limited Liability Com. Meridian Inv Counsel owns 10,000 shares for 0% of their portfolio.

The stock of Curis Inc (NASDAQ:CRIS) registered an increase of 17.45% in short interest. CRIS’s total short interest was 1.20 million shares in December as published by FINRA. Its up 17.45% from 1.02M shares, reported previously. With 228,000 shares average volume, it will take short sellers 5 days to cover their CRIS’s short positions. The short interest to Curis Inc’s float is 4.39%.

The stock decreased 4.23% or $0.033 during the last trading session, reaching $0.747. About 281,172 shares traded or 0.09% up from the average. Curis, Inc. (NASDAQ:CRIS) has declined 85.15% since December 7, 2017 and is downtrending. It has underperformed by 100.77% the S&P500.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $24.74 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

More notable recent Curis, Inc. (NASDAQ:CRIS) news were published by: Zacks.com which released: “Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates – Zacks.com” on August 02, 2018, also Seekingalpha.com with their article: “Curis: One Swallow Doesn’t Make A Summer – Seeking Alpha” published on November 22, 2016, Benzinga.com published: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs (July 29-Aug. 4) – Benzinga” on July 28, 2018. More interesting news about Curis, Inc. (NASDAQ:CRIS) were released by: Nasdaq.com and their article: “Why Curis, Inc. Is Soaring Today – Nasdaq” published on May 31, 2018 as well as Benzinga.com‘s news article titled: “Benzinga Pro’s 5 Stocks To Watch Today (MDGL)(AKS)(AKER)(BURL)(CRIS) – Benzinga” with publication date: May 31, 2018.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.